about
Analysis of the human MutLalpha.MutSalpha complexAllosteric activation of the protein kinase PDK1 with low molecular weight compoundsSubstrate-selective inhibition of protein kinase PDK1 by small compounds that bind to the PIF-pocket allosteric docking siteBone morphogenetic protein-9 induces epithelial to mesenchymal transition in hepatocellular carcinoma cellsCholecystokinin stimulates extracellular signal-regulated kinase through activation of the epidermal growth factor receptor, Yes, and protein kinase C. Signal amplification at the level of Raf by activation of protein kinase CepsilonSerum autotaxin is a parameter for the severity of liver cirrhosis and overall survival in patients with liver cirrhosis--a prospective cohort studySerum microRNA-21 as marker for necroinflammation in hepatitis C patients with and without hepatocellular carcinomaSoluble serum CD81 is elevated in patients with chronic hepatitis C and correlates with alanine aminotransferase serum activity.Serum miR-122 as a biomarker of necroinflammation in patients with chronic hepatitis C virus infection.Interleukin-22 predicts severity and death in advanced liver cirrhosis: a prospective cohort study.Serum microRNA-122 predicts survival in patients with liver cirrhosis.Diagnostic and prognostic significance of cell death and macrophage activation markers in patients with hepatocellular carcinoma.Differential stability of cell-free circulating microRNAs: implications for their utilization as biomarkers.MicroRNA Profiling of Laser-Microdissected Hepatocellular Carcinoma Reveals an Oncogenic Phenotype of the Tumor CapsuleMutations in the MutSalpha interaction interface of MLH1 can abolish DNA mismatch repair.Low 25-Hydroxyvitamin D Levels Are Associated with Infections and Mortality in Patients with Cirrhosis.Gadoxetate acid-enhanced MRI of hepatocellular carcinoma in a c-myc/TGFα transgenic mouse model including signal intensity and fat content: initial experience.Reduced efficacy of the Plk1 inhibitor BI 2536 on the progression of hepatocellular carcinoma due to low intratumoral drug levels.Serum sphingolipidomic analyses reveal an upregulation of C16-ceramide and sphingosine-1-phosphate in hepatocellular carcinoma.TGF-β1 and TGF-β2 abundance in liver diseases of mice and menThe role of recent nanotechnology in enhancing the efficacy of radiation therapy.An Allosteric Inhibitor Scaffold Targeting the PIF-Pocket of Atypical Protein Kinase C Isoforms.High levels of the soluble programmed death-ligand (sPD-L1) identify hepatocellular carcinoma patients with a poor prognosis.Physico-chemical and toxicological characterization of iron-containing albumin nanoparticles as platforms for medical imaging.Biodegradable human serum albumin nanoparticles as contrast agents for the detection of hepatocellular carcinoma by magnetic resonance imaging.Inhibition of the equilibrative nucleoside transporter 1 and activation of A2A adenosine receptors by 8-(4-chlorophenylthio)-modified cAMP analogs and their hydrolytic products.Regulation of the interaction between protein kinase C-related protein kinase 2 (PRK2) and its upstream kinase, 3-phosphoinositide-dependent protein kinase 1 (PDK1).Epac activation converts cAMP from a proliferative into a differentiation signal in PC12 cells.RNAse A-like enzymes in serum inhibit the anti-neoplastic activity of siRNA targeting polo-like kinase 1.Vesicle-associated microRNAs are released from blood cells on incubation of blood samples.Inhibition of RNAse A family enzymes prevents degradation and loss of silencing activity of siRNAs in serum.Hypoxia Causes Downregulation of Dicer in Hepatocellular Carcinoma, Which Is Required for Upregulation of Hypoxia-Inducible Factor 1α and Epithelial-Mesenchymal Transition.High Serum Levels of the Interleukin-33 Receptor Soluble ST2 as a Negative Prognostic Factor in Hepatocellular Carcinoma.Improving Drug Penetrability with iRGD Leverages the Therapeutic Response to Sorafenib and Doxorubicin in Hepatocellular Carcinoma.Application of IL-36 receptor antagonist weakens CCL20 expression and impairs recovery in the late phase of murine acetaminophen-induced liver injury.Detection of hepatocellular carcinoma in transgenic mice by Gd-DTPA- and rhodamine 123-conjugated human serum albumin nanoparticles in T1 magnetic resonance imaging.Regulation of protein kinase C-related protein kinase 2 (PRK2) by an intermolecular PRK2-PRK2 interaction mediated by Its N-terminal domain.Dimerization of the hepatitis C virus nonstructural protein 4B depends on the integrity of an aminoterminal basic leucine zipper.The cytoskeletal inhibitors latrunculin A and blebbistatin exert antitumorigenic properties in human hepatocellular carcinoma cells by interfering with intracellular HuR trafficking.Influence of amantadine on CD81 expression on lymphocytes in chronic hepatitis C.
P50
Q24300627-04B64BB3-3978-4BC3-AAE7-9B1ED3771362Q24317058-0ADD15D4-8EBB-43D5-B513-8FC1140D65E4Q27682391-B87B65F1-97B7-4FCD-A37C-78281B71044EQ28282426-04C17433-F826-45AE-90A4-8513550928EFQ28573986-29A7A6E5-D024-4921-AB32-A65BE4DD1282Q33952500-21377D52-9DD5-421A-A38A-5F514A06D6FBQ34069652-C5FA5E20-B812-432E-8546-0627C0F3E66BQ34166233-6E7EAFFF-ED3E-479E-9EBC-DB86A1A23455Q34186933-EF5DE846-7290-4BE4-B9D3-AA94C81C147EQ34411311-CF952A66-DDC2-41DF-A939-8CF12D80A0AEQ34429711-3148474B-311A-4341-8A2D-36C4214C48BCQ34781109-2A1A156A-65E1-474C-B791-E432E637922EQ35000824-17CA18AB-F23E-4EA9-A682-0B8C04A55644Q35028814-EFA3E5CC-C804-41A6-9CDA-FD456094DDBBQ35537125-8916F697-981E-4AB7-ABD2-421E53869FF4Q35677400-7A423B49-17FA-4467-86A1-712A5986AEA8Q35909487-12D7AF61-2C90-4DD2-99B0-D702F6D2D24AQ36062154-E5A1FE94-969D-4941-9FFC-0E434D70C88DQ37109693-92DF7524-A2E4-4901-B7A2-CDCA5182E5ABQ37190089-B21F7E69-CC43-4C59-BF6E-EFBEE88F7FEBQ38542775-A13F867A-428E-45D5-B345-836F5B815232Q38723169-8AA461EE-DEA4-422C-9F12-56742F52D2EAQ38886747-1A3775DE-440C-4C0A-A361-ED2886FAC167Q38961400-095459A6-6774-4993-BAFD-1CF103D75302Q39040827-07CCCED3-442F-4FC1-9E90-6013FDE50DB8Q39791808-4C5F788D-AB31-48F8-A582-8DE79466001BQ39805182-A7EBBB73-BAD7-4FB0-BC0D-43424066EC3AQ39847587-ABADE8D7-F883-4358-AE0A-7287082F17A9Q40160584-B61C433A-05F4-436E-9D0C-B021FDA477E5Q40273642-B82A2D8D-09D2-4C20-8A4A-10999F439C9CQ40336502-A649B434-A152-4552-9E84-689D4260D4C3Q40342791-0509BDD2-590D-4715-AA77-BBE26A26DF0FQ40917751-728709E8-46FD-4A66-9D37-93A7A30E7EE9Q41074002-197F1EA4-0995-49F5-8307-15415678BE7EQ41480019-D822C687-AF30-4966-8A9D-D22F6FAAC48AQ41699836-457D643E-ED67-4326-ABD6-522D5D6E5468Q41858762-C8DEE34C-2A85-4288-B9DE-309A264568A4Q42232834-017C22A0-BDCC-405A-9BCB-ED618E7DBE34Q42465949-793AD408-7E70-431E-812D-4AF0269C0ABAQ42996988-8C040280-47BD-48E6-BFE8-64B4244DB718
P50
description
onderzoeker
@nl
researcher ORCID ID = 0000-0003-0131-3669
@en
name
Albrecht Piiper
@ast
Albrecht Piiper
@en
Albrecht Piiper
@es
Albrecht Piiper
@nl
type
label
Albrecht Piiper
@ast
Albrecht Piiper
@en
Albrecht Piiper
@es
Albrecht Piiper
@nl
prefLabel
Albrecht Piiper
@ast
Albrecht Piiper
@en
Albrecht Piiper
@es
Albrecht Piiper
@nl
P106
P31
P496
0000-0003-0131-3669